Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Journal of Aesthetic Nursing ; 12(2):75-77, 2023.
Article in English | CINAHL | ID: covidwho-2271582

ABSTRACT

In this regular feature, aesthetic nurse Claudia McGloin presents a brief synopsis of a range of recently published articles on medical aesthetics. Research roundup aims to provide an overview, rather than a detailed summary and critique, of the papers selected. Should you wish to look at any of the papers in more detail, a full reference is provided at the end of each study summary

2.
J Pediatr Rehabil Med ; 13(3): 273-279, 2020.
Article in English | MEDLINE | ID: covidwho-949027

ABSTRACT

PURPOSE: After the onset of the Coronavirus pandemic of 2019-2020 (COVID-19), physicians who inject OnabotulinumtoxinA (BoNT-A) were left with determining risks and benefits in pediatric patients with cerebral palsy. Many of these patients have pre-existing conditions that make them more prone to COVID-19 symptoms, and this susceptibility potentially increases after BoNT-A injections. METHODS: A retrospective chart review of 500 patients identified 256 pediatric patients with cerebral palsy who received an intramuscular BoNT-A injection to determine relative doses used for each Gross Motor Functional Classification Score (GMFCS). Data regarding age, weight, GMFCS, BoNT-A total body dosage, and inpatient hospitalizations for 6 months post-injection were collected. Differences between GMFCS levels were analyzed using one-way analysis of variance testing. Inpatient hospitalizations were recorded and assessed using relative risk to determine the population risk of hospitalization in the setting of initiating injections during the COVID-19 pandemic. RESULTS: Based on GMFCS level, patients who were GMFCS I or II received fewer units of BoNT-A medication per kilogram of body weight compared to GMFCS III-V (p< 0.0005, F= 25.38). There was no statistically significant difference in frequency or time to hospitalization when comparing patients receiving BoNT-A compared to a control group. CONCLUSIONS: Resumption of BoNT-A injections during the time of COVID-19 requires a systematic approach based on risks and potential benefits. Data from this analysis does not show increased risk for patients who received injections historically; however, recommendations for resumption of injections has not previously been proposed in the setting of a pandemic. In this manuscript, a tiered approach to considerations for injections was proposed. Botulinum toxin type A injections have a history of improving spasticity in the pediatric patient with cerebral palsy. Ensuring appropriate selection of patients for injection with BoNT-A during this pandemic is increasingly important.


Subject(s)
Botulinum Toxins, Type A/administration & dosage , COVID-19/epidemiology , Cerebral Palsy/drug therapy , Neuromuscular Agents/administration & dosage , Pandemics , COVID-19/prevention & control , COVID-19/transmission , Case-Control Studies , Child , Dose-Response Relationship, Drug , Drug Administration Schedule , Humans , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Injections, Intramuscular , Patient Selection , Personal Protective Equipment , Retrospective Studies , United States/epidemiology , Vulnerable Populations
SELECTION OF CITATIONS
SEARCH DETAIL